Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial

Chloé Gervès-Pinquié, Fatima Daumas-Yatim, Benoît Lalloué, Anne Girault, Marie Ferrua, Aude Fourcade, François Lemare, Mario Dipalma, Etienne Minvielle, Chloé Gervès-Pinquié, Fatima Daumas-Yatim, Benoît Lalloué, Anne Girault, Marie Ferrua, Aude Fourcade, François Lemare, Mario Dipalma, Etienne Minvielle

Abstract

Background: The emergence of oral delivery in cancer therapeutics is expected to result in an increased need for better coordination between all treatment stakeholders, mainly to ensure adequate treatment delivery to the patient. There is significant interest in the nurse navigation program's potential to improve transitions of care by improving communication between treatment stakeholders and by providing personalized organizational assistance to patients. The use of health information technology is another strategy aimed at improving cancer care coordination that can be combined with the NN program to improve remote patient follow-up. However, the potential of these two strategies combined to improve oral treatment delivery is limited by a lack of rigorous evidence of actual impact.

Methods/design: We are conducting a large scale randomized controlled trial designed to assess the impact of a navigation program denoted CAPRI that is based on two Nurse Navigators and a web portal ensuring coordination between community and hospital as well as between patients and navigators, versus routine delivery of oral anticancer therapy. The primary research aim is to assess the impact of the program on treatment delivery for patients with metastatic cancer, as measured by Relative Dose Intensity. The trial involves a number of other outcomes, including tumor response, survival, toxic side effects, patient quality of life and patient experience An economic evaluation adopting a societal perspective will be conducted, in order to estimate those health. care resources' used. A parallel process evaluation will be conducted to describe implementation of the intervention.

Discussion: If the CAPRI program does improve treatment delivery, the evidence on its economic impact will offer important knowledge for health decision-makers, helping develop new follow-up services for patients receiving oral chemotherapy and/or targeted therapy. The process evaluation will determine the best conditions in which such a program might be implemented.

Trial registration: NCT 02828462 . Registered 29 June 2016.

Trial registration: ClinicalTrials.gov NCT02828462.

Figures

Fig. 1
Fig. 1
Flow Chart of participant’s progress through the different phases of the study

References

    1. Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: Challenges and opportunities. J Controlled Release. 2013;170:15–40. doi: 10.1016/j.jconrel.2013.04.020.
    1. Agboola S, Flanagan C, Searl M, Elfiky A, Kvedar J, Jethwani K. Improving outcomes in cancer patients on oral anti-cancer medications using a novel mobile phone-based intervention: study design of a randomized controlled trial. JMIR Res Protoc. 2014;3:e79. doi: 10.2196/resprot.4041.
    1. Spoelstra SL, Given BA, Given CW, Grant M. Policy Implications of Oral Agents. Semin Oncol Nurs. 2011;27:161–5. doi: 10.1016/j.soncn.2011.02.008.
    1. Spoelstra SL, Given CW. Assessment and Measurement of Adherence to Oral Antineoplastic Agents. Semin Oncol Nurs. 2011;27:116–32. doi: 10.1016/j.soncn.2011.02.004.
    1. Spoelstra SL, Given BA, Given CW, Grant M, Sikorskii A, You M, et al. An Intervention to Improve Adherence and Management of Symptoms for Patients Prescribed Oral Chemotherapy Agents: An Exploratory Study. Cancer Nurs. 2013;36:18–28. doi: 10.1097/NCC.0b013e3182551587.
    1. Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review. Cancer Treat Rev. 2013;39:610–21. doi: 10.1016/j.ctrv.2012.12.014.
    1. Bassan F, Peter F, Houbre B, Brennstuhl M, Costantini M, Speyer E, et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl) 2014;23:22–35. doi: 10.1111/ecc.12124.
    1. McCue DA, Lohr LK, Pick AM. Improving Adherence to Oral Cancer Therapy in Clinical Practice. Pharmacother J Hum Pharmacol Drug Ther. 2014;34:481–94. doi: 10.1002/phar.1399.
    1. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66. doi: 10.3322/caac.20004.
    1. Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007;334:407. doi: 10.1136/bmj.39069.489757.55.
    1. Eschiti V, Burhansstipanov L, Watanabe-Galloway S. Native Cancer Navigation: The State of the Science. Clin J Oncol Nurs. 2012;16:73–89. doi: 10.1188/12.CJON.73-82.
    1. Wilcox B, Bruce SD. Patient navigation: a “win-win” for all involved. Oncol Nurs Forum. 2010;37:21–5. doi: 10.1188/10.ONF.21-25.
    1. Hopkins J, Mumber MP. Patient navigation through the cancer care continuum: an overview. J Oncol Pract. 2009;5:150–2. doi: 10.1200/JOP.0943501.
    1. Wells KJ, Meade CD, Calcano E, Lee J-H, Rivers D, Roetzheim RG. Innovative approaches to reducing cancer health disparities: the Moffitt Cancer Center Patient Navigator Research Program. J. Cancer Educ. Off. J. Am. Assoc. J Cancer Educ. 2011;26:649–57. doi: 10.1007/s13187-011-0238-7.
    1. McMullen L. Oncology nurse navigators and the continuum of cancer care. Semin Oncol Nurs. 2013;29:105–17. doi: 10.1016/j.soncn.2013.02.005.
    1. Kroenke K, Theobald D, Wu J, Norton K, Morrison G, Carpenter J, et al. Effect of telecare management on pain and depression in patients with cancer: a randomized trial. JAMA. 2010;304:163–71. doi: 10.1001/jama.2010.944.
    1. McCann L, Maguire R, Miller M, Kearney N. Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care (Engl) 2009;18:156–64. doi: 10.1111/j.1365-2354.2008.00938.x.
    1. Clifford S, Perez-Nieves M, Skalicky AM, Reaney M, Coyne KS. A systematic literature review of methodologies used to assess medication adherence in patients with diabetes. Curr Med Res Opin. 2014;30:1071–85. doi: 10.1185/03007995.2014.884491.
    1. Schneider SM, Hess K, Gosselin T. Interventions to Promote Adherence With Oral Agents. Semin Oncol Nurs. 2011;27:133–41. doi: 10.1016/j.soncn.2011.02.005.
    1. Kvedar J, Coye MJ, Everett W. Connected Health: A Review Of Technologies And Strategies To Improve Patient Care With Telemedicine And Telehealth. Health Aff (Millwood) 2014;33:194–9. doi: 10.1377/hlthaff.2013.0992.
    1. Jean-Pierre P, Hendren S, Fiscella K, Loader S, Rousseau S, Schwartzbauer B, et al. Understanding the processes of patient navigation to reduce disparities in cancer care: perspectives of trained navigators from the field. J. Cancer Educ. Off. J. Am. Assoc. J Cancer Educ. 2011;26:111–20. doi: 10.1007/s13187-010-0122-x.
    1. Hoverman JR, Klein I, Harrison DW, Hayes JE, Garey JS, Harrell R, et al. Opening the Black Box: The Impact of an Oncology Management Program Consisting of Level I Pathways and an Outbound Nurse Call System. J Oncol Pract. 2014;10:63–7. doi: 10.1200/JOP.2013.001210.
    1. Schneider SM, Adams DB, Gosselin T. A tailored nurse coaching intervention for oral chemotherapy adherence. J Adv Pract Oncol. 2014;5:163.
    1. Khandelwal N, Duncan I, Ahmed T, Rubinstein E, Pegus C. Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions. J Natl Compr Cancer Netw JNCCN. 2012;10:618–25.
    1. Lairson DR, Huo J, Ball Ricks KA, Savas L, Fernández ME. The cost of implementing a 2-1-1 call center-based cancer control navigator program. Eval Program Plann. 2013;39:51–6. doi: 10.1016/j.evalprogplan.2013.04.001.
    1. Kimman ML, Dirksen CD, Voogd AC, Falger P, Gijsen BCM, Thuring M, et al. Economic evaluation of four follow-up strategies after curative treatment for breast cancer: Results of an RCT. Eur J Cancer. 2011;47:1175–85. doi: 10.1016/j.ejca.2010.12.017.
    1. Hendren S, Fiscella K. Patient navigation improves the care experience for patients with newly diagnosed cancer. J Clin Oncol. 2014;32:3–4. doi: 10.1200/JCO.2013.53.2960.
    1. Girault A, Ferrua M, Lalloué B, Sicotte C, Fourcade A, Yatim F, et al. Internet-based technologies to improve cancer care coordination: Current use and attitudes among cancer patients. Eur J Cancer. 2015;51:551–7. doi: 10.1016/j.ejca.2014.12.001.
    1. Lyman GH, Dale DC, Tomita D, Whittaker S, Crawford J. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat. 2013;139:863–72. doi: 10.1007/s10549-013-2582-2.
    1. Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH, ANC Study Group Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100:255–62. doi: 10.1007/s10549-006-9254-4.
    1. Miyake H, Miyazaki A, Harada K-I, Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol Northwood Lond Engl. 2014;31:978. doi: 10.1007/s12032-014-0978-4.
    1. Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, et al. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. Clin. Genitourin. Cancer. 2016;in press.
    1. Kyrios M, Nedeljkovic M, Moulding R, Klein B, Austin D, Meyer D, et al. Study protocol for a randomised controlled trial of internet-based cognitive-behavioural therapy for obsessive-compulsive disorder. BMC Psychiatry. 2014;14:209. doi: 10.1186/1471-244X-14-209.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet Lond Engl. 2001;357:1191–4. doi: 10.1016/S0140-6736(00)04337-3.
    1. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78–93. doi: 10.3322/canjclin.54.2.78.
    1. Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20:417–35. doi: 10.1007/s10552-008-9256-0.
    1. Ovretveit J. Evaluating Improvement and Implementation for Health. Maidenhead: Open University Press; 2014.
    1. Olomu AB, Stommel M, Holmes-Rovner MM, Prieto AR, Corser WD, Gourineni V, et al. Is quality improvement sustainable? Findings of the American College of Cardiology’s Guidelines Applied in Practice. Int J Qual Health Care. 2014;26:215–22. doi: 10.1093/intqhc/mzu030.
    1. Lee CR, Nicholson PW, Souhami RL, Slevin ML, Hall MR, Deshmukh AA. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer. 1993;67:630–4. doi: 10.1038/bjc.1993.115.
    1. Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer Oxf Engl 1990. 2006;42:2271–6.
    1. Craven O, Hughes CA, Burton A, Saunders MP, Molassiotis A. Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer: Nurse-led telephone follow-up in oral chemotherapy. Eur J Cancer Care (Engl) 2013;22:413–9. doi: 10.1111/ecc.12047.
    1. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–50. doi: 10.1016/j.jval.2013.02.002.
    1. Krzyzanowska MK. Time to Get Serious About Improving the Safety of Oral Chemotherapy. J Oncol Pract. 2013;9:1s–2s. doi: 10.1200/JOP.2013.000913.
    1. Busse R, World Health Organization, European Observatory on Health Systems and Policies. Tackling chronic disease in Europe strategies, interventions and challenges [Internet]. Copenhagen: World Health Organization on behalf of the European Observatory on Health Systems and Policies; 2010 [cited 2014 Sep 11]. Available from:
    1. Portela MC, Pronovost PJ, Woodcock T, Carter P, Dixon-Woods M. How to study improvement interventions: a brief overview of possible study types. BMJ Qual Saf. 2015;24:325–36. doi: 10.1136/bmjqs-2014-003620.
    1. Rahurkar S, Vest JR, Menachemi N. Despite The Spread Of Health Information Exchange, There Is Little Evidence Of Its Impact On Cost, Use And Quality Of Care. Health Aff (Millwood) 2015;34:477–83. doi: 10.1377/hlthaff.2014.0729.
    1. Wulff CN, Thygesen M, Søndergaard J, Vedsted P. Case management used to optimize cancer care pathways: A systematic review. BMC Health Serv Res. 2008;8:227. doi: 10.1186/1472-6963-8-227.
    1. Nielsen K. Review Article: How can we make organizational interventions work? Employees and line managers as actively crafting interventions. Hum Relat. 2013;66:1029–50. doi: 10.1177/0018726713477164.
    1. Nielsen K, Taris TW, Cox T. The future of organizational interventions: Addressing the challenges of today’s organizations. Work Stress. 2010;24:219–33. doi: 10.1080/02678373.2010.519176.
    1. Eccles M, Grimshaw J, Campbell M, Ramsay C. Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual Saf Health Care. 2003;12:47–52. doi: 10.1136/qhc.12.1.47.
    1. Avery AK, Del Toro M, Caron A. Increases in HIV screening in primary care clinics through an electronic reminder: an interrupted time series. BMJ Qual Saf. 2014;23:250–6. doi: 10.1136/bmjqs-2012-001775.
    1. Benn J, Burnett S, Parand A, Pinto A, Vincent C. Factors predicting change in hospital safety climate and capability in a multi-site patient safety collaborative: a longitudinal survey study. BMJ Qual Saf. 2012;21:559–68. doi: 10.1136/bmjqs-2011-000286.
    1. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. The BMJ. 2015;350:h1258. doi: 10.1136/bmj.h1258.
    1. Oakley A, Strange V, Bonell C, Allen E, Stephenson J. Process evaluation in randomised controlled trials of complex interventions. BMJ. 2006;332:413–6. doi: 10.1136/bmj.332.7538.413.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55. doi: 10.1097/00000421-198212000-00014.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74. doi: 10.1097/00005650-198601000-00007.
    1. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J. Clin. Oncol. Off. J. Am. Soc. Clin. J Clin Oncol. 1993;11:1189–97.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer Oxf Engl 1990. 2009;45:228–47.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76. doi: 10.1093/jnci/85.5.365.
    1. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM. Development and validation of the Patient Assessment of Chronic Illness Care (PACIC) Med Care. 2005;43:436–44. doi: 10.1097/01.mlr.0000160375.47920.8c.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe